Breaking Research News from sources other than Breastcancer.org
Comments
-
Lumpie thank you for the editorial. One of the topics I discussed with my MO just yesterday and she told me the same.
I very much appreciate what you are doing here, posting so many good sources. Thank you.
0 -
Thank you Lumpie, you are such a knowledgeable source for BC information. I don't see John Smith here anymore? He was also a great source regarding new treatments and trials. I read recently somewhere that the 5 year survival rate for bone mets only BC patients was 70%.
Wife Update: My wife is TNBC and has bone mets only. She endures miserable SE from Halaven but after the first 2 push infusions her calcium suddenly dropped from high 10.8's to an acceptable level of 9.7. PET scan soon so we will find out then. Her oncologist doesn't believe in TM's much.
0 -
New to this thread and learned a lot reading today. Thank you so much Lumpie and everyone.
Santa Barbarian
0 -
Very glad to know that this forum is helpful to many who have chimed in!
Mike, I am not sure about John Smith and wife. Perhaps he or a friend will see your post and offer an update. Hope they are both doing well.
I'll be posting some interesting news/links I have recently located. My work schedule is pretty demanding right now so the timing may be a little erratic - sorry.
0 -
Researchers discover potential new approach to block growth of HER2 positive breast cancer
https://www.news-medical.net/news/20180830/Researc...
Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. Their findings were published today in Cell Metabolism.
August 30, 2018
0 -
Green tea prevent cancer cells from 'refuelling'
https://www.salford.ac.uk/news/articles/2018/green...
In research published in the journal Aging, a team from the Biomedical Research Centre at the University of Salford, used metabolic phenotyping on cell lines of breast cancer stem cells and found that Matcha "shifted cancer cells towards a quiescent metabolic state" and stopped their spread at a relatively low concentration (0.2 mg/ml).
"By using metabolic phenotyping, we found that the tea is suppressing oxidative mitochondrial metabolism – in other words it is preventing the cells from 're-fuelling' and therefore they become inactive and die.
http://www.aging-us.com/article/101483
published: August 23, 2018
0 -
Wow, Lumpie, I didn't even know what Matcha was! Very interesting. I think I want the cancer cells working and lively while I'm hitting them with Ibrance, though ???? A lot of this is way too complicated for me. However, this is very good information and I hope the researchers will absolutely figure out how to use this tea most effectively along with treatments or even instead of! Maybe along with future immunotherapy? It's exciting to see how many angles are being investigated which I hope and pray will converge into practical treatments (dare I say cures?) very soon.
0 -
Lumpie - thanks for all the time you take to research & post. I was particularly interested in the HER2+ article & will be discussing that with my MO at my next appointment.
0 -
Muddling: Yes, lots of interesting research being done. I hope some of it will progress quickly!
0 -
Study Tracks the Evolution of Treatment Resistance in Metastatic Breast Cancer
November 7, 2017, by NCI Staff
Findings from a new study provide fresh insights into the treatment of women with metastatic breast cancer whose tumors are no longer responding to available treatments.
https://www.cancer.gov/news-events/cancer-currents...
0 -
LBBC: Conference on MBC - April 2018
Page provides links to recorded live stream from the conference. Topics include:
- Exercise & Breast Cancer
- Sexual Health & Breast Cancer
- Yoga & Breast Cancer
- Ask the Experts & Managing Symptoms and Side Effects
- Diet & Breast Cancer
- Clinical Trials, Hot Topics & Scientist Panel Discussion
0 -
Study finds new clues to understand relapse in breast cancer
A large genomic analysis has linked certain DNA mutations to a high risk of relapse in estrogen receptor positive breast cancer, while other mutations were associated with better outcomes... The knowledge could help predict which patients are most likely to have their cancer return and spread, and could help guide treatment decisions. The study appears Sept. 4 (2018) in the journal Nature Communications.
https://www.news-medical.net/news/20180904/Study-f...
0 -
Researchers reveal an unlikely protector against growth of metastatic breast cancer
"Many people study primary tumors and the assumption has been that metastases grow the same way. But our work suggests that, while inflammation can help tumor cells escape and land elsewhere in the body, if inflammation is there when they land, it keeps the cells in check. When inflammation is suppressed, the cells grow out."
Another study "uncovered a connection between metastasis and a common drug used to treat osteoporosis. In that study, the team found that bisphosphonates could affect bone marrow cells in a way that stopped the growth of breast cancer cells that had spread to the bones. However, they also found evidence that a specific protein - granulocyte-colony stimulating factor (G-CSF) - can help cancer cells overcome this effect. Women with high levels of G-CSF did worse on bisphosphonates than women with low levels of G-CSF."
paper published online in Nature Cell Biology on Aug. 27 (2108)
0 -
In one of the posts above, someone asked about links to live stream video from the 2018 ASCO conference. I think that I had a link at one time but I cannot locate it now. Here are a few links that may be helpful:
The ASCO conference page for Patient Advocates. It includes a information on....
- "2018 ASCO Annual Meeting Videos: Consider a 2018 ASCO Annual Meeting Videos subscription, which provides access to the Meeting presentations. A discounted rate is available exclusively for patients, survivors, and caregivers. Contact us for more information."
https://am.asco.org/patient-advocates
If you want to *purchase* access, you can do so here ($452!):
http://shop.asco.org/amslv18_2018-annual-meeting-v...
The ASCO YouTube page
https://www.youtube.com/user/ASCOcancer
ASCO social media links:
https://am.asco.org/arc/social-media
Here's a link to a few video interviews of "Best of ASCO® 2018 Miami Symposium." It's free, but I don't think that any are on Breast Cancer.
https://ecancer.org/conference/videos/1073-best-of...
Will post other interesting links if I locate any....
0 -
Lumpie, thanks for the links, especially the ones from the LBBC conference on MBC. Really good!
0 -
Axillary Dissection vs No Axillary Dissection in Patients With Breast Cancer and Sentinel-Node Micrometastases
- Original source: The Lancet Oncology
- https://www.practiceupdate.com/C/73090/56?elsca1=e...
0 -
At Least 15 Men Near Ground Zero Have Breast Cancer
Many exposed to the WTC site appear to experience a greater cancer burden
- Source: HealthDay
- At least 15 men who worked near Ground Zero after the 9/11 attacks have been diagnosed with breast cancer, a New York City law firm claims. Some studies have concluded that those exposed to the World Trade Center site, including firefighters and recovery workers, "will experience a greater cancer burden than would be expected from a demographically similar population," according to CBS.
0 -
Case Report Describes 4 Breast Cancer Cases Post Transplant
case report published recently in the American Journal of Transplantation.
https://www.practiceupdate.com/C/73276/56?elsca1=e...
...reported four cases of breast cancer transmission to transplant recipients from a single organ donor. The donor had no relevant medical history and donated her kidneys, lungs, liver, and heart. ...four recipients developed donor-derived breast cancer, which was proven by DNA microsatellite. As a result of the donor-derived breast cancer, the double-lung recipient, left-kidney recipient, and liver recipient died. After diagnosis of the breast cancer in the right-kidney recipient, the patient underwent transplant nephrectomy, his immunosuppression was stopped, chemotherapy was initiated, and despite having widely metastasized disease he achieved complete remission.
"This extraordinary case points out the often fatal consequences of donor-derived breast cancer and suggests that removal of the donor organ and restoration of immunity can induce complete remission," the authors write.
0 -
Breast Pathologic Complete Response to Neoadjuvant Chemotherapy and Nodal Positivity Rate
- Original source: JAMA Surgery
- This study evaluated a large cancer database including 30,821 patients with cT1/cT2 N0/N1 breast cancer treated with neoadjuvant chemotherapy and surgical resection. Those with cT1/cT2, cN0 ERBB2-positive or triple-negative breast cancer who achieved a breast pathologic complete response had less than a 2% rate of axillary nodal positivity.
- Patients with cN0 ERBB2-positive or triple-negative breast cancer and who have an excellent response to neoadjuvant chemotherapy have an extremely low rate of nodal positivity at surgery, which supports the consideration of omission of axillary surgery in these patients.
{Note: ERBB2-positive is HER2+}0 -
Limitations in the Effect of Screening on Breast Cancer Mortality
- Original source: Journal of Clinical Oncology
- https://www.practiceupdate.com/C/72949/56?elsca1=e...
0 -
Tumor-Associated Macrophages in Breast Cancer: Innocent Bystander or Important Player?
Original source: Cancer Treatment Reviews
https://www.practiceupdate.com/C/72788/56?elsca1=e...
- Tumor-associated macrophages (TAMs) are related to poor prognosis in breast cancer. TAMs promote breast cancer cell growth, invasion, and metastasis preclinically.
- TAMs mediate treatment resistance in breast cancer and are a potential therapeutic target in patients with breast cancer.
0 -
Lumpie, I have to thank you again for your work here. It´s trully helpful what you share...
Esp. your today´s post of "Axillary Dissection vs No Axillary Dissection in Patients With Breast Cancer and Sentinel-Node Micrometastases" is interesting for me, as I had 4 sentinnel nodes removed and one had micrometastazes. The article really gives me peace of mind. Wow, no difference to ALDN at 10 years.
0 -
Much Touted For Cancer, 'Precision Medicine' Often Misses The Target
https://khn.org/news/is-precision-medicine-the-ans...
Doctors and hospitals love to talk about the patients they've saved with precision medicine, and reporters love to write about them. But the people who die still vastly outnumber the rare successes. In a large study published last year in Cancer Discovery, precision medicine failed to help 93 percent of the 1,000 patients who signed up for the study. At the most recent meeting of the American Society of Clinical Oncology — the largest cancer meeting in the world — researchers presented four precision-medicine studies. Two were total failures. The other two weren't much better, failing to shrink tumors 92 percent and 95 percent of the time. The studies received almost no news coverage.
Some experts say that such testing should be available to everyone with advanced cancer, because no one can predict which individual might have a rare mutation that can be targeted with a new or experimental drug. When patients respond to these drugs, they tend to do very well, and some survive much longer than expected.
{This article was also published in the New York Times.}
0 -
JaBoo, You are most welcome and thanks for your feedback. Very glad to know this has provided some peace of mind!
0 -
Adjuvant Dose-Dense Doxorubicin-Cyclophosphamide vs Docetaxel-Doxorubicin-Cyclophosphamide for High-Risk Breast Cancer
- Originally published in: European Journal of Cancer
- https://www.practiceupdate.com/C/72259/56?elsca1=e...
0 -
Found it! It's not the whole conference but this may be of interest to some....
Report Back From ASCO on Metastatic Breast Cancer
Receive the latest information on metastatic breast cancer advancements as presented at the American Society of Clinical Oncology Conference by Dr. Mark E. Robson, medical oncologist, Chief of Breast Medicine Serve at MSKCC. This webinar took place on August 6, 2018.
https://www.sharecancersupport.org/report-back-fro...
0 -
Thanks, Lumpie!
0 -
Disease-Free and Overall Survival in Operable HER2+ Breast Cancer Treated With Sequential vs Concurrent Chemotherapy
- Originally published in: JAMA Oncology
- https://www.practiceupdate.com/C/73070/56?elsca1=e...
0 -
Fulvestrant + Goserelin vs Anastrozole + Goserelin vs Goserelin Alone in HR+, HER2− Premenopausal Women With Recurrent/Metastatic Breast Cancer
- Study published in: European Journal of Cancer
- https://www.practiceupdate.com/C/73455/56?elsca1=e...
0 -
Accurate Classification of BRCA1 Variants With Saturation Genome Editing
Study published in: Nature
https://www.practiceupdate.com/C/73409/56?elsca1=e...
- The authors of this study report on single-nucleotide variants identified in 13 exons involved in the expression of BRCA1. In particular, the authors highlight 300 nonfunctional missense mutations and 300 mutations that disrupt expression of BRCA1.
- The authors suggest that identifying single-nucleotide variants associated with pathological expression of BRCA1 should be of use in the oncology clinic.
0
